HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
JAGX
Jaguar Health, Inc.
There isn't enough reported data to score JAGX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
JAGX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
JAGX's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
JAGX PE Valuation
JAGX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
JAGX Forward outlook
There aren't enough analyst estimates for JAGX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
JAGX has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus JAGX down 107%.
JAGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$12,059.25 | +$167,905.50 |
| Q3 2025 | -$83,359.50 | +$378,891.45 |
| Q2 2025 | -$93,843.75 | +$653,875.95 |
| Q1 2025 | -$141,482.25 | +$883,962.45 |
| Q4 2024 | -$179,964.75 | +$2,680,354.95 |
JAGX lost $12,059.25 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over JAGX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over JAGX on profitability, with a higher operating margin.
JAGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.2M | -59% |
| Q1 2026 | $20.3M | +816% |
| Q4 2025 | $3.2M | -7.8% |
| Q3 2025 | $3.1M | -0.8% |
| Q4 2020 | $2.6M | +71% |
| Q3 2020 | $2.8M | +185% |
JAGX's revenue is growing: $1M last quarter, down 59% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -620% | -351 points |
| Q1 2026 | 50% | +476 points |
| Q4 2025 | -657% | -424 points |
| Q3 2025 | -235% | -1.1 points |
| Q2 2025 | -269% | N/A |
| Q1 2025 | -426% | N/A |
| Q4 2024 | -232% | N/A |
| Q3 2024 | -234% | N/A |
JAGX's operating margin was −620% last quarter, down 351 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
JAGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $8.8M | +$16.1M |
| Q1 2025 | -$7.3M | -$269K |
| Q4 2024 | -$7.8M | -$375K |
| Q3 2024 | -$6.3M | +$449K |
| Q1 2024 | -$7M | +$2.9M |
| Q4 2023 | -$7.5M | -$1M |
| Q3 2023 | -$6.8M | +$1.7M |
| Q1 2023 | -$9.9M | -$2.3M |
JAGX has burned cash in almost every quarter: −$12M over the past year, against −$28M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over JAGX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
JAGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1772% | +51.1K shares |
| 1 year | +7455% | +53.2K shares |
| 3 years | +5394000% | +53.9K shares |
JAGX has 53,941 diluted shares, up 7455% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
JAGX Net Leverage
JAGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
JAGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 0.1 | Oversold |
JAGX's weekly RSI is 28 (oversold) and its Stochastic is 0 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
JAGX PE vs Healthcare Sector
JAGX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
JAGX has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus JAGX above 0 of 4.
JAGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.02 | 87% below |
| 20 week MA | $11.0 | 96% below |
| 50 week MA | $179.7 | 100% below |
| 100 week MA | $2,208.0 | 100% below |
JAGX is in a downtrend: it's below all four of its weekly moving averages, and 100% below its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over JAGX on returns for 2026, with the stronger performance.
JAGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $16,800.0 | $13,518.8 | -20% |
| 2025 | $13,518.8 | $572.3 | -96% |
| 2026 YTD | $572.3 | $0.40 | -100% |
JAGX has finished every year since 2024 lower, and it's down 100% so far in 2026.